Clinical Study to Investigate the PK Profiles and Safety of CKD-385 in Healthy Volunteers Under Fed Conditions

NCT04906785 | Unknown Phase 1

• 1 other identifier: A88_11BE2110
• Study Type: interventional
• Target: 52
• Locations: 1 country
• Sites: 1

Brief Summary

Clinical Study to Investigate the PK Profiles and Safety of CKD-385 in Healthy Volunteers Under Fed Conditions

Conditions

Cardiovascular Diseases

Outcome Measures

Primary Outcomes (1)

• AUCt of CKD-385

  Area under the concentration-time curve from time zero to time of CKD-385

  Pre-dose (0 hour), 1, 2, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 8, 10, 12, 24, 48 hours

Secondary Outcomes (5)

• AUCinf of CKD-385

  Pre-dose (0 hour), 1, 2, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 8, 10, 12, 24, 48 hours

• Tmax of CKD-385

  Pre-dose (0 hour), 1, 2, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 8, 10, 12, 24, 48 hours

• T1/2 of CKD-385

  Pre-dose (0 hour), 1, 2, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 8, 10, 12, 24, 48 hours

• CL/F of CKD-385

  Pre-dose (0 hour), 1, 2, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 8, 10, 12, 24, 48 hours

• Vd/F of CKD-385

  Pre-dose (0 hour), 1, 2, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 8, 10, 12, 24, 48 hours

Study Arms (2)

Sequence1

EXPERIMENTAL

1. Period 1: Reference drug(D744) 2. Period 2: Test drug(CKD-385)

Drug: CKD-385; Drug: D744

Sequence2

EXPERIMENTAL

1. Period 1: Test drug(CKD-385) 2. Period 2: Reference drug(D744)

Drug: CKD-385; Drug: D744

Interventions

CKD-385 DRUG

Test Drug

Sequence1; Sequence2

D744 DRUG

Reference Drug

Sequence1; Sequence2

Eligibility Criteria

• Age: 19 Years - 54 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy adults age≥19 years and age\<55 years at the time of screening
• Individuals who had 17.5 kg/m2 ≤ Body Mass Index(BMI) \< 30.5kg/m2 and men's total body weight ≥ 55 kg, women's total body weight ≥ 45 kg
• \* BMI = Weight(kg)/ Height(m)2
• Individuals without congenital/chronic diseases and without abnormal symptoms or diagnosis based on a medical examination within the last 3 years
• Individuals who were deemed to be appropriate as study subjects following laboratory tests (hematology, blood chemistry, urinalysis, viral/ bacterial, etc.) and vital signs, ECG etc. performed at screening
• Individuals who signed an informed consent form approved by the IRB of Chonbuk National University Hospital and decided to participate in the study after being fully informed of the study prior to participation, including the objective, content and characteristics of the investigational product
• Individuals who agreed proper contraception during the study and did consent to not donation of sperm 1 month after the last dose of study drug infusion
• Individuals with the ability and willingness to participate the entire study period

You may not qualify if:

• Subject who has (or has histories of) clinically significant blood, kidney, endocrine, respiratory, gastrointestinal, urinary, cardiovascular, liver, mental, neurological or allergic diseases(except for asymptomatic seasonal allergy at the time of administration) or evidence(except for simple dental history such as dental calculus, impacted tooth, wisdom tooth, etc.)
• Subject with a history of gastrointestinal disorders(esophageal achalasia or esophagus stenosis, Crohn's disease) or gastrointestinal surgery(except for simple appendicitis surgery or hernia surgery or tooth extraction surgery) that may affect the absorption of drug
• Subject who shows the following values as a result of laboratory tests
• \*ALT or AST \> 2 times upper limit of normal range
• Subject who has a history of regular alcohol consumption in excess of 210 g/week within 6 months of screening
• Subject who smokes more than one pack of cigarette a day within 6 months of screening
• Subject who took other clinical trial drugs or bioequivalence test drugs within 3 months before the first administration of clinical trial drug
• Subject who conform to the specific items below
• systolic blood pressure less than 90 mmHg, greater than 140 mmHg or diastolic blood pressure less than 60 mmHg or greater than 90 mmHg in a sitting position
• Severe bradycardia (less than 50 beats/minute)
• Subject who has significant alcohol abuse or drug abuse within a year of screening
• Subject who took drugs which are known as disturbing drug metabolism within 30 days prior to the first administration of clinical trial drug.
• Subject who uses any of other drugs, including over-the-counter medications and prescription medications within 10 days prior to first administration of clinical trial drug.
• Subject who donated whole blood within 2 months prior to first administration of clinical trial drug or blood components within 1 month prior to first administration of clinical trial drug
• Subject who is hypersensitive to the components of a clinical trial drug or clinical trial drug itself.

Sponsors & Collaborators

• Chong Kun Dang Pharmaceutical: lead

Study Sites (1)

National University Hospital

Jeonju, South Korea

Location

MeSH Terms

Conditions

Cardiovascular Diseases

Study Officials

• Min-Gul Kim

  Chonbuk National University Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Min-Gul Kim

CONTACT

+82632593480; mgkim@jbcp.kr

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 27, 2021
• First Posted: May 28, 2021
• Study Start: June 4, 2021
• Primary Completion: July 30, 2021
• Study Completion: August 6, 2021
• Last Updated: May 28, 2021

Record last verified: 2021-05

Data Sharing

• IPD Sharing: Will not share

Locations

KR (1)